IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript Summary
IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript Summary
Gross profit increased by 41% to $1.03 million, and gross margin improved to 43% from the previous year's 37%.The following is a summary of the IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript:
以下是IceCure Medical Ltd (ICCM) 2024年第三季度業績會的摘要：
Financial Performance:
財務表現：
ProSense systems and disposable probe sales increased by 36% to $2.32 million for the nine months ending September 30, 2024, compared to the previous year.
Total revenue grew by 22% to $2.42 million in the same period, driven by higher sales in Europe, the US, and Japan.
Gross profit increased by 41% to $1.03 million, and gross margin improved to 43% from the previous year's 37%.
ProSense系統和一次性探頭的銷售額增長了36%，達到232萬美元，截止到2024年9月30日的九個月裏，相比於去年。
總營業收入在同一時期增長了22%，達到了242萬美元，得益於在歐洲、美國和日本的銷售增長。
毛利潤增長了41%，達到103萬美元，毛利率從去年的37%改善至43%。
Business Progress:
業務進展：
Completed the ICE3 trial with positive outcomes, potentially leading to FDA marketing authorization for ProSense.
Engaged in the PRECISE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, using ProSense in a larger patient population.
Partnered with Terumo Corporation in Japan to file for regulatory approval of ProSense for breast cancer in 2025.
完成了ICE3試驗，並取得積極成果，可能導致FDA對ProSense的市場授權。
參與了PRECISE研究，該研究由Umberto Veronesi基金會和意大利衛生部資助，使用ProSense在更大患者人群中進行。
與日本的Terumo Corporation合作，計劃於2025年申請ProSense用於乳腺癌的監管批准。
Opportunities:
機會：
The potential FDA authorization of ProSense in Q1 2025 could significantly boost the U.S. market presence.
Upcoming catalysts in 2025 include interim results from the ICESECRET study and additional regulatory approvals in Japan.
2025年第一季度ProSense潛在的FDA授權可能會顯著提升其在美國市場的影響力。
2025年即將發生的催化劑包括ICESECREt研究的中期結果和日本的額外監管批准。
Risks:
風險：
There remains uncertainty regarding the exact timing for FDA marketing authorization and the approach of the FDA in terms of special controls and post-marketing requirements.
關於FDA市場授權的確切時間以及FDA在特殊控制和市場後要求方面的做法仍存在不確定性。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
